Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

271

HTML

2839

Figures (1-2)

241

Tables (1-5)

185

Sum=3536

Mar 14, 2005 (publication date) through Nov 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Mar 14, 2005; 11(10): 1445-1451
Published online Mar 14, 2005. doi: 10.3748/wjg.v11.i10.1445

Full Size Figure Download Figure

Figure 2 Disease-free analyses of HCC patients segregated into negative and positive expression of EMMPRIN protein (P = 0. 087).

Citation: Li HG, Xie DR, Shen XM, Li HH, Zeng H, Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 2005; 11(10): 1445-1451
URL: https://www.wjgnet.com/1007-9327/full/v11/i10/1445.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i10.1445